Mirabegron (Betmiga) for the indication overactive bladder syndrome
The WAR approved the pharmacotherapeutic report of the medicine mirabegron (Betmiga). Its therapeutic value was determined via comparison with tolterodine (muscarinic receptor antagonist). They reached the following conclusions: the therapeutic value of mirabegron for the symptomatic treatment of urgency, increased micturition frequency and/or urgency incontinence, as may occur in adult patients with overactive bladder syndrome, is equal to that of tolterodine.